Clinical Trial Update: S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update describing a study comparing S1 versus pemetrexed plus carboplatin in patients with EGFR wild-type, nonsquamous non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)
• S1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Sun Yat-sen University | Conditions: NSCLC | Phase 2 | Status: UNKNOWN